Egalet, a developer of treatments for pain and other conditions, has hired Patrick Shea as Chief Commercial Officer (CCO).
Shea will be responsible for leading Egalet's commercial activities and will report to Bob Radie, Chief Executive Officer.
In his role he will develop and implement the commercialisation strategy for Oxaydo (oxycodone HCI, USP) tablets for oral use only, Sprix (ketorolac tromethamine) nasal spray, Arymo ER (morphine sulfate) extended-release tablets, which are under review at the US Food and Drug Administration and additional Guardian Technology pipeline products as they are developed.
He has more than two decades of sales, marketing, market access and commercial operations experience.
Most recently he was CCO at Clarus Therapeutics, a men's health speciality pharmaceutical company.
Prior to this he was Vice President of Sales and Marketing for the US commercial operations of CSL Behring.
Before that he was Senior Vice President of Sales and Marketing for the US pharmaceutical operations at Astellas Pharmaceuticals, and held senior sales and marketing roles at Ligand Pharmaceuticals and Boehringer Ingelheim.
